The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

ELI LILLY'S ZEPBOUND REDUCES TYPE 2 DIABETES RISK, STUDY SHOWS. The pharmaceutical giant announced in August it was offering 2.5 mg and 5 mg single-dose vials of tirzepatide for the first time in ...

Eli Lilly said it has started selling single-dose vials of its uber-popular weight loss drug Zepbound as demand soars – and the smaller doses cost 50% less than all other obesity medicines.

Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 medications have risen in popularity. Investor Alert: Our 10 best stocks ...